Home > Insider Trading > Filing (0000899243-18-013086)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1285819	Omeros Corp	OMER	Pharmaceutical Preparations (2834)	911663741

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1529087	A Michael Jacobsen	201 Elliott Avenue West Seattle WA 98119	Vp Finance And Cao	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-05-14	10,980	$9.37	19,480	No	4	M	Direct
Common Stock	Disposition	2018-05-14	10,980	$22.45	8,500	No	4	S	Direct
Common Stock	Acquisiton	2018-05-15	12,812	$9.37	21,312	No	4	M	Direct
Common Stock	Disposition	2018-05-15	12,812	$24.95	8,500	No	4	S	Direct
Common Stock	Acquisiton	2018-05-15	5,000	$9.37	13,500	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option(Right to Buy)	Disposition	2018-05-14	10,980	$0.00	10,980	$9.37
Common Stock	Stock Option(Right to Buy)	Disposition	2018-05-15	12,812	$0.00	12,812	$9.37
Common Stock	Stock Option(Right to Buy)	Disposition	2018-05-15	5,000	$0.00	5,000	$9.37

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
47,000	2023-09-24	No	4	M	Direct
34,188	2023-09-24	No	4	M	Direct
29,188	2023-09-24	No	4	M	Direct

Footnotes

Open market sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2017, at which time the trading schedule, including sale periods, price and the number of shares to be sold, was established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
25% of the total number of shares subject to this option vested on September 3, 2014, and the remaining shares subject to the option vested and became exercisable in equal monthly installments over the 36 months following the initial vesting date.
On May 15, 2018, the reporting person paid the exercise price and exercised options to purchase 5,000 shares of the company's common stock. These shares have not been sold and are held for the account of the reporting person. The options exercised in this transaction have the same vesting terms described in footnote 2.